» Articles » PMID: 26498057

Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled Study

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2015 Oct 27
PMID 26498057
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We determined the effect of testosterone solution 2% on total testosterone level and the 2 symptoms of hypogonadism, sex drive and energy level.

Materials And Methods: This was a randomized, multicenter, double-blind, placebo controlled, 16-week study to compare the effect of testosterone and placebo on the proportion of men with a testosterone level within the normal range (300 to 1,050 ng/dl) upon treatment completion. We also assessed the impact of testosterone on sex drive and energy level measured using SAID (Sexual Arousal, Interest and Drive scale) and HED (Hypogonadism Energy Diary), respectively. A total of 715 males 18 years old or older with total testosterone less than 300 ng/dl and at least 1 symptom of testosterone deficiency (decreased energy and/or decreased sexual drive) were randomized to 60 mg topical testosterone solution 2% or placebo once daily.

Results: Of study completers 73% in the testosterone vs 15% in the placebo group had a testosterone level within the normal range at study end point (p <0.001). Participants assigned to testosterone showed greater baseline to end point improvement in SAID scores (low sex drive subset p <0.001 vs placebo) and HED scores (low energy subset p = 0.02 vs placebo, not significant at prespecified p <0.01). No major adverse cardiovascular or venous thrombotic events were reported in the testosterone group. The incidence of increased hematocrit was higher with testosterone vs placebo (p = 0.04).

Conclusions: Once daily testosterone solution 2% for 12 weeks was efficacious in restoring normal testosterone levels and improving sexual drive in hypogonadal men. Improvement was also seen in energy levels on HED though not at the prespecified p <0.01. No new safety signals were identified.

Citing Articles

Testosterone supplementation and stroke in young adults: a review of the literature.

Dengri C, Koriesh A, Babi M, Mayberry W, Goldstein E, Pervez M Front Neurol. 2024; 15:1422931.

PMID: 39286801 PMC: 11402820. DOI: 10.3389/fneur.2024.1422931.


The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.

Cruickshank M, Hudson J, Hernandez R, Aceves-Martins M, Quinton R, Gillies K Health Technol Assess. 2024; 28(43):1-210.

PMID: 39248210 PMC: 11404359. DOI: 10.3310/JRYT3981.


Management of male obesity-related secondary hypogonadism: A clinical update.

Shenoy M, Mondal S, Fernandez C, Pappachan J World J Exp Med. 2024; 14(2):93689.

PMID: 38948417 PMC: 11212738. DOI: 10.5493/wjem.v14.i2.93689.


Social Perceptions of Masculinity and Sexual Esteem Are Impacted by Viagra Use, Testosterone, and Sexual Performance.

Hawley W, Cancilla B, Barnes J, Morrow G Arch Sex Behav. 2024; 53(7):2473-2488.

PMID: 38740630 DOI: 10.1007/s10508-024-02880-y.


Diagnosis and treatment of hypogonadism in men seeking to preserve fertility - what are the options?.

Lockie A, Grice P, Mathur R, Pearce I, Modgil V Int J Impot Res. 2024; 37(2):109-113.

PMID: 38693209 DOI: 10.1038/s41443-024-00897-4.